Peptide approval status in the EU
Where each of the 68 compounds stands in the EU, from the European Medicines Agency’s and national registers, checked October 7, 2026.
This summarizes approval status. It isn’t legal advice: rules on importing, prescribing and possessing medicines differ and change. “No marketing authorization” means no approved product was found, nothing more.
- SemaglutideApproved drug
- EMA-authorized, prescription only: Ozempic (2018) and Rybelsus (2020) for type 2 diabetes; Wegovy (2022) for weight management in adults and teens 12+, now also as tablets.
- TirzepatideApproved drug
- EMA-authorized, prescription only, as Mounjaro (September 2022): type 2 diabetes from age 10, and weight management in adults. Sleep apnea and heart failure aren’t authorized uses.
- RetatrutideHuman studies
- No marketing authorization.
- CagrilintideHuman studies
- No marketing authorization; EMA lists no cagrilintide or CagriSema product.
- AOD9604Human studies
- No marketing authorization. FDA’s 2024 search found no listing with the European Medicines Agency and no European Pharmacopoeia monograph.
- 5-Amino-1MQPreclinical
- No marketing authorization.
- SLU-PP-332Preclinical
- No marketing authorization.
- L-CarnitineApproved drug
- No EU-wide (EMA) authorization; authorized nationally, for example in Spain as a prescription IV injection and oral solution since 1980.
- HGH Fragment 176-191Preclinical
- No marketing authorization.
- LiraglutideApproved drug
- EMA-authorized, prescription only: Victoza (2009), type 2 diabetes from age 10; Saxenda (2015), weight management from age 12, and from age 6 since 2025. Two more brands in 2026.
- ExenatideApproved drug
- No longer authorized. EMA lists Byetta (authorized 2006) and Bydureon (2011) as withdrawn from January 1, 2026.
- SurvodutideHuman studies
- No marketing authorization.
- MazdutideApproved drug
- No marketing authorization.
- OrforglipronApproved drug
- No marketing authorization as of October 2026; EMA lists no orforglipron product.
- TesofensineHuman studies
- No marketing authorization.
- NAD+Human studies
- No marketing authorization as a medicine.
- MOTS-cPreclinical
- No marketing authorization; FDA’s 2026 review found no product containing MOTS-c authorized by the EMA.
- SS-31Approved drug
- No marketing authorization. EMA granted orphan designations for Barth syndrome (2021) and a mitochondrial DNA depletion syndrome (2022); these aren’t approvals.
- GlutathioneApproved drug
- No EU-wide authorization. In Italy, glutathione injections (TAD and others) are prescription medicines to prevent chemotherapy nerve damage, first authorized in 1989.
- EpithalonPreclinical
- No marketing authorization; FDA’s 2026 review found no EMA-authorized product, and none in Belgium, France, Germany, Ireland, Italy, Norway or Spain.
- HumaninPreclinical
- No marketing authorization; no humanin product has been authorized anywhere.
- FOXO4-DRIPreclinical
- No marketing authorization; no FOXO4-DRI product is approved anywhere, and it has never been tested in people.
- BPC-157Preclinical
- No marketing authorization. FDA’s 2026 review found no approved BPC-157 product in any country.
- TB-500Preclinical
- No marketing authorization. FDA’s 2026 review found no TB-500 product authorized by the European Medicines Agency or in the EU countries it checked.
- KPVPreclinical
- No marketing authorization. FDA found no KPV product authorized by the European Medicines Agency and no monograph in the European Pharmacopoeia.
- ARA-290Human studies
- No marketing authorization. EMA granted orphan designations for sarcoidosis (2013) and for preventing graft loss in pancreatic islet transplantation (2016); both are still listed.
- CartalaxPreclinical
- No marketing authorization; no medicine containing cartalax is approved anywhere.
- MGFPreclinical
- No marketing authorization; no MGF product is authorized by the European Medicines Agency.
- PEG-MGFPreclinical
- No marketing authorization; no PEG-MGF product is authorized by the European Medicines Agency.
- Thymosin Beta-4Human studies
- No marketing authorization, and EMA’s orphan register lists no thymosin beta-4 designation.
- LarazotideHuman studies
- No marketing authorization; larazotide has never been approved anywhere.
- CJC-1295 (no DAC)Preclinical
- No marketing authorization. FDA’s 2024 review found no CJC-1295 product authorized by the EMA or approved in any EU country it checked.
- CJC-1295 with DACHuman studies
- No marketing authorization. FDA’s 2024 review found no CJC-1295 product authorized by the EMA or approved in any EU country it checked.
- IpamorelinHuman studies
- No marketing authorization; FDA’s 2024 search of the EMA and national registries found no ipamorelin product.
- SermorelinHuman studies
- No current marketing authorization found. Geref 50, a one-dose diagnostic test, was licensed in Ireland from 1991 until its withdrawal in July 2007.
- TesamorelinApproved drug
- No marketing authorization. Ferrer withdrew its EMA application in June 2012, after EMA’s experts provisionally found the benefits didn’t outweigh the risks, citing IGF-1 rises and no long-term data.
- IGF-1 LR3Preclinical
- No marketing authorization; it has never been tested as a medicine. Mecasermin (Increlex), a different molecule, is the EU-authorized IGF-1 drug.
- GHRP-2Approved drug
- No marketing authorization. Japan’s regulator reported in 2014 that it wasn’t approved or marketed outside Japan.
- GHRP-6Human studies
- No marketing authorization.
- HexarelinHuman studies
- No marketing authorization; it was never marketed.
- MK-677Human studies
- No marketing authorization. The EU granted orphan designation for GH deficiency in June 2017, which isn’t an approval.
- IGF-1 DESPreclinical
- No marketing authorization; it has never been tested as a medicine. Mecasermin (Increlex), full-length IGF-1, is the EU-authorized IGF-1 drug.
- Follistatin-344Preclinical
- No marketing authorization; no follistatin product is approved. ACE-083, a follistatin-based drug, reached phase 2 trials with European sites before being stopped in 2020.
- GHK-CuHuman studies
- No marketing authorization as a medicine. Listed in the EU cosmetic ingredient database (CosIng) as copper tripeptide-1, a skin-conditioning ingredient, with no restriction in the Cosmetics Regulation annexes.
- AHK-CuPreclinical
- No marketing authorization as a medicine. In the EU cosmetic ingredient database, the matching entry appears to be alanine/histidine/lysine polypeptide copper HCl, a skin-conditioning ingredient with no restrictions.
- SNAP-8Human studies
- No marketing authorization as a medicine. Listed in the EU cosmetic ingredient database (CosIng) as acetyl octapeptide-3, a humectant and skin-conditioning ingredient, with no annex restriction.
- Melanotan 1Approved drug
- Authorized since December 2014, under exceptional circumstances, as Scenesse implant for adults with EPP, prescribed at specialist porphyria centers. No tanning product is authorized.
- Melanotan 2Human studies
- No marketing authorization; no melanotan II product is authorized by the European Medicines Agency.
- ArgirelineHuman studies
- No marketing authorization as a medicine. Listed in the EU cosmetic ingredient database (CosIng) as acetyl hexapeptide-8, a humectant and skin-conditioning ingredient, with no restriction in the Cosmetics Regulation annexes.
- MatrixylHuman studies
- No marketing authorization as a medicine. Listed in the EU cosmetic ingredient database (CosIng) as palmitoyl pentapeptide-4, a skin-conditioning ingredient, with no restriction in the Cosmetics Regulation annexes.
- hCGApproved drug
- Prescription only. Recombinant Ovitrelle is EU-authorized (2001); urine-derived hCG is licensed nationally, for example as Gonasi, Zivafert, Choriomon and Chorapur.
- Kisspeptin-10Human studies
- No marketing authorization. FDA’s 2024 review found no approved kisspeptin-10 product in any country.
- PT-141Approved drug
- No marketing authorization; EMA’s medicines database has no bremelanotide product.
- OxytocinApproved drug
- Prescription only. Oxytocin injections such as Syntocinon are licensed nationally for labor and bleeding after birth; EMA’s 2021 list also showed Syntocinon nasal sprays in five European countries.
- GonadorelinApproved drug
- No EU-wide authorization. Licensed nationally in some countries: France’s Lutrelef (3.2 mg, for pump therapy) has a valid, marketed authorization.
- TriptorelinApproved drug
- No central EU license. Prescription medicines under national licenses as Decapeptyl, Diphereline, Gonapeptyl, Pamorelin, Salvacyl and others (EMA list, 2022).
- SelankApproved drug
- No marketing authorization: not in EMA’s database of medicines authorized in EU and EEA countries (September 2026).
- SemaxApproved drug
- No marketing authorization: not in EMA’s database of medicines authorized in EU and EEA countries (September 2026).
- AdamaxPreclinical
- No marketing authorization: not in EMA’s database of medicines authorized in EU and EEA countries (September 2026).
- DSIPApproved drug
- No marketing authorization: EMA’s database lists no DSIP product. A German product named Deltaran is an unrelated painkiller (dexibuprofen).
- CerebrolysinApproved drug
- Authorized nationally in Austria, Bulgaria, Croatia, the Czech Republic, Latvia, Lithuania, Poland, Romania and Slovakia (EMA database, September 2026). Not authorized EU-wide.
- PinealonPreclinical
- No marketing authorization; no medicine containing pinealon is approved anywhere.
- DihexaHuman studies
- No marketing authorization: not in EMA’s database of medicines authorized in EU and EEA countries (September 2026).
- PE-22-28Preclinical
- No marketing authorization: not in EMA’s database of medicines authorized in EU and EEA countries (September 2026).
- Thymosin Alpha-1Approved drug
- Authorized nationally only in Italy, since 1993: Zadaxin, prescription only, as an add-on to flu vaccination in people with weakened immunity. No EU-wide authorization.
- ThymalinApproved drug
- No marketing authorization; it’s a registered medicine in Russia, not in the EU.
- VIPApproved drug
- Not authorized alone. With phentolamine, Invicorp is authorized nationally for erectile dysfunction in Denmark, Finland, France, Germany and Sweden. EU orphan designations, not approvals, cover lung diseases, including ARDS (2026).
- LL-37Human studies
- No marketing authorization; no LL-37 product is authorized by the European Medicines Agency.